Media Room
Our last news
Events
IRE ELiT and Grand Pharmaceutical Co., Ltd. announce partnership for Galli Eo (Gallium-68 generator) distribution in China
Fleurus (Belgium) and Wuhan (China), 06 June 2024, – IRE ELiT, a leading global player in the field of radiopharmaceuticals, is pleased to announce the signing of a distribution agreement with Grand Pharmaceutical (China) Co., Ltd. (“Grand Pharma”, and its subsidiary Chengdu Purevalley Medical Technology Co., Ltd.), a major pharmaceutical conglomerate, for the distribution of its Galli Eo (Gallium-68 generator) in China. This strategic partnership underscores IRE ELiT’s commitment to expanding its footprint in one of the most dynamic and rapidly growing markets for radiopharmaceuticals.
IRE moves to 100% LEU (Low-Enriched Uranium) conversion
Fleurus, Belgium, March 28th, 2023 – The Institute for Radioelements (IRE), world leader in the production of molybdenum-99 (Mo-99), the most widely used radioisotope in nuclear medicine for diagnosis, and iodine-131 (I-131) essential and irreplaceable radionuclide for thyroid cancer treatments, announced today the complete conversion of its production process to low-enriched uranium (LEU).
Ground-breaking ceremony for RECUMO
From 2026 onwards, the nuclear research centre SCK CEN will transform radioactive residues into low-enriched uranium and will purify them in its brand new RECUMO facility. These residues resulting from the production of medical radioisotopes on the site of the Institut National des Radioéléments (IRE). Today, the first sod was turned for the RECUMO building. With it, IRE and SCK CEN are literally creating a European first on Belgian soil.
The fight against cancer intensified thanks to SCK CEN and the IRE
SCK CEN, the Belgian Nuclear Research Centre, and the National Institute for Radioelements (IRE) are going to start the large-scale production of lutetium-177. This decision, validated today by the signature of the two partners, opens up opportunities for cancer patients. Among other things, this radioisotope is very promising for the treatment of prostate cancer. This type of cancer is responsible for 90,000 deaths each year in Europe.
SMART takes critical step towards the production of medical isotope Mo-99 without uranium
Fleurus, 22 February 2022 – Since 2018, the National Institute for Radioelements (IRE) has been working with the Dutch company ASML on the SMART project. Its goal: to develop a new technology to produce a radioisotope that is crucial to nuclear medicine, without using uranium. February 2022 marks a turning point in the future of this ambitious project since a proof of concept test has recently validated the main principles of this unprecedented technology. This is a major step in the design and engineering phase, the success of which will allow confirmation of technical choices during 2022 in preparation for the Board of Directors’ decision regarding investment in an industrial facility.
First commercial deliveries of I-131 based on LEU from IRE plant
Fleurus, Belgium 1st February 2021 - IRE is pleased to announce that its first commercial deliveries of I-131 based on the irradiation of Low Enriched Uranium (LEU) targets have started this week.
IRE ELiT submitted Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the 100 mCi Ge68/Ga68 Galli Eo® generator.
Cardinal Health (NYSE: CAH) and IRE ELiT (the radiopharmaceutical subsidiary of IRE Group) are working to expand patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging as demand in the United States (U.S.) continues to grow. Cardinal Health is the preferred U.S. distributor of the IRE ELiT 100 mCi Germanium-68/Gallium-68 radionuclide generator (Ge-68/Ga-68 Galli Eo® generator) in support of clinical investigational trials, pre-commercial research and post-approval commercial sales in the U.S. and its territories, including Puerto Rico.
IRE submits its request for a single permit for the construction of a 100% Walloon cyclotron
In 2020, IRE signed a contract with IBA to build a cyclotron on its site in Fleurus. This state-of-the-art equipment will enable the IRE to produce Germanium-68 locally, a key raw material to enable the institute to contribute even more to the fight against cancer. The IRE is pursuing the progress of this project by submitting today an application for a single permit (urban planning and environmental permit).